India's Everest Organics making API for Merck's COVID-19 drug
12 October 2021 -

Everest Organics Ltd (BOM:524790), an Indian manufacturer of bulk pharmaceutical drugs and intermediates, has said that it had started making the active pharmaceutical ingredient (API) for a generic version of Merck & Co's (NYSE:MRK) molnupiravir, an experimental antiviral drug to treat mild to moderate COVID-19, Reuters news agency reported on Tuesday.

The company reportedly joins Divi's Laboratories Ltd as an API maker for Merck's experimental oral drug.

Merck has separately entered into voluntary licensing agreements with at least eight Indian generic drugmakers for molnupiravir, aiming to turn the country into a manufacturing hub for the drug.

The pharmaceutical company has sought US emergency use authorisation for the drug, putting molnupiravir on course to become the first oral antiviral medication for COVID-19, Reuters noted.



Related Headlines